matrine, (5beta)-isomer has been researched along with irinotecan in 1 studies
| Studies (matrine, (5beta)-isomer) | Trials (matrine, (5beta)-isomer) | Recent Studies (post-2010) (matrine, (5beta)-isomer) | Studies (irinotecan) | Trials (irinotecan) | Recent Studies (post-2010) (irinotecan) |
|---|---|---|---|---|---|
| 11 | 0 | 11 | 8,002 | 1,885 | 3,752 |
| Protein | Taxonomy | matrine, (5beta)-isomer (IC50) | irinotecan (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 2.7 | |
| Interstitial collagenase | Homo sapiens (human) | 6.06 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.556 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 3.171 | |
| Acetylcholinesterase | Homo sapiens (human) | 1.827 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.9 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 4.7667 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, J; Jing, D; Liang, X; Liu, X; Rashid, HU; Wang, H; Wang, L; Wu, L; Xie, P; Xu, Y | 1 |
1 other study(ies) available for matrine, (5beta)-isomer and irinotecan
| Article | Year |
|---|---|
Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Proliferation; Drug Design; Female; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Structure-Activity Relationship; Topoisomerase I Inhibitors | 2018 |